Efficacy and Safety of SYNB1618 in Adult Patients With Phenylketonuria
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, single-arm
study of a SYNB1618 dose-ramp regimen. All evaluations and assessments throughout this study
may be conducted either at the clinical site or by a home healthcare professional at an
alternative location (e.g., patient's home, hotel).